Michael Miller, PhD, has conducted infectious disease and immunology research for more than 30 years. After completing a postdoctoral fellowship studying the HIV integrase enzyme at The Salk Institute for Biological Studies, Mike began his pharmaceutical industry career at Merck. During 18 years working in antiviral drug discovery at Merck, Mike and his team advanced more than two dozen anti-HIV and anti-HCV compounds into clinical development, ultimately leading to marketing approvals for four drugs including a first-in-class HIV integrase inhibitor.  He then moved to Oncology Regulatory Affairs to support early and late clinical development of immuno-oncology products. In that role, Mike led marketing application submissions to expand the oncology indications for Merck’s PD-1 inhibitor. He later served as Vice President and Head of Global Regulatory Affairs at Idera Pharmaceuticals, Senior Vice President and Head of Regulatory Affairs at AlloVir, Inc., and most recently as Senior Vice President and Head of Regulatory Affairs at Venatorx, Inc. Mike is a co-author on more than 100 peer-reviewed scientific publications.  He holds a BA in Microbiology from the University of Kansas and a PhD in Immunology from Harvard University.